Activation of the STAT3 signaling pathway predicts poor survival in diffuse large B-cell lymphoma pa

• 作 者: KaiFu;
• 机 构: University of Nebraska Medical Center,Omaha,NE,USA
• 出 处: 22nd Asia Pacific Cancer Conference(第22届亚太抗癌大会)
• 发表日期: 2013年期

　　Diffuse large B-cell lymphoma (DLBCL) is one of the most common forms of adult non-Hodgkin lymphoma (NHL).The addition of rituximab to standard CHOP chemotherapy regimens results in an improved overall survival rate of 10% to15%.A substantial number of patients still die of the disease,highlighting the need for improved DLBCL prognostication and better therapy.DLBCL is a biologically and clinically heterogeneous disease that can be divided into two main subgroups: germinal center B-cell-like (GCB) DLBCL and activated B-cell-like (ABC) DLBCL.GCB-DLCBL represents transformed GC centroblasts that highly express the GC master regulator BCL6 and lack features of B-cell activation.